Industry
Industry
Sponsored by
10 principles summarizing SynBalance's belief about taking care of people’s health.
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology, which provides greater…
First and only FDA-approved orally administered microbiota-based therapeutic, validating Seres’ microbiome platform –
The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to…
The bacterial strains in MB097 were identified by analysing the microbiome of patients in multiple studies of ICIs in melanoma.
Industry, Video
Sponsored by
Marco Caspani, Executive Director of the Microbiome Division of Sacco System, explains how the company is directing his efforts and strong focus to the field of Biotherapeutics with the launch of…
The first-in-human study double-blind, placebo controlled, 28-day crossover study of the safety and tolerability of SB-121
Gabriel Leventhal, Chief Scientific Officer at Pharmabiome, spoke about NicheMap, a reference database that allows us to select the most appropriate strains to engineer targeted changes in the microbiome.
Colette Shortt, Regulatory Specialist and Visiting Professor University of Ulster, spoke about the regulatory framework for food supplements and Live Biotherapeutic products.
Hepatic encephalopathy is a debilitating and recurring condition that causes neuropsychiatric conditions and is a common complication of cirrhosis.
